Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R.
Formato: Artigo
Idioma:Inglês
Publicado: American Diabetes Association 2013
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://ncbi.nlm.nih.gov/pubmed/23412078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2391
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares